Mr. Masashi Wakaokawa of JP Morgan Securities (Vice President, Stock Research Department, Market Research Division) stated that "In recent years, Daiichi Sankyo's evaluation has been on the rise along with the growth of Enhertus." Since the launch of HER2-positive breast cancer treatment in the USA in January 2020, Daiichi Sankyo has expanded the indications for Enhertus to multiple countries and diseases. As a result, the stock price, which was in the 2000 yen range in 2019, reached the 3000 yen range by mid-2020.
In 2021, the overall market became conservative, causing stocks with anticipated future growth to underperform. Dragged down by this trend, Daiichi Sankyo's stock price also declined, temporarily falling below 2000 yen in August of the same year. As an individual factor, there was concern about the outcome of arbitration with U.S.-based Seagen, Inc. regarding the rights to ADC (according to Mr. Wakaokawa). As a result, the company's stock price fluctuated between the 2000 yen range and 3000 yen range until the end of 2021.
However, since announcing the achievement of the primary endpoint in the phase 3 clinical trial of Enhertus for HER2-low expressed breast cancer patients (DESTINY-Breast04 trial, hereinafter DB04 trial) in February 2022, the company's stock price began to be reassessed...
In 2021, the overall market became conservative, causing stocks with anticipated future growth to underperform. Dragged down by this trend, Daiichi Sankyo's stock price also declined, temporarily falling below 2000 yen in August of the same year. As an individual factor, there was concern about the outcome of arbitration with U.S.-based Seagen, Inc. regarding the rights to ADC (according to Mr. Wakaokawa). As a result, the company's stock price fluctuated between the 2000 yen range and 3000 yen range until the end of 2021.
However, since announcing the achievement of the primary endpoint in the phase 3 clinical trial of Enhertus for HER2-low expressed breast cancer patients (DESTINY-Breast04 trial, hereinafter DB04 trial) in February 2022, the company's stock price began to be reassessed...
Translated
$Apple (AAPL.US)$
Buy when the three principles of investment fall. 2 do not know the market, continue to stay in a small amount to buy 3 markets. Take time as your own side. That's not true. In September, the continuing chaotic market is not so much a rise as a horizontal repetition of decline, which is why we need to be patient. I don't know the bottom, but I don't know. Maybe there's the best shopping place somewhere.Tesla, Inc. and Apple Inc were separated in August 2020. I think we all know which is better. Inflation is the biggest stumbling block in this division, but we are waiting for the big wave somewhere before the final accounts, the mid-term elections and the end of the year. I bought it in addition before that.
Buy when the three principles of investment fall. 2 do not know the market, continue to stay in a small amount to buy 3 markets. Take time as your own side. That's not true. In September, the continuing chaotic market is not so much a rise as a horizontal repetition of decline, which is why we need to be patient. I don't know the bottom, but I don't know. Maybe there's the best shopping place somewhere.Tesla, Inc. and Apple Inc were separated in August 2020. I think we all know which is better. Inflation is the biggest stumbling block in this division, but we are waiting for the big wave somewhere before the final accounts, the mid-term elections and the end of the year. I bought it in addition before that.
Translated